Most shockwave therapy protocols for erectile dysfunction call for one or two sessions per week, with a total course of six to twelve sessions. The most common schedule studied in clinical trials is one session per week for six weeks, though some clinics use a compressed format of two sessions per week for three weeks, followed by a three-week break, then another three-week round. Both approaches deliver a similar total number of treatments.
The Standard Treatment Schedule
There is no single universally agreed-upon protocol, which is part of the reason this question is hard to get a straight answer on. Clinical trials have tested schedules ranging from five total sessions to twelve, with one or two visits per week. The two most widely studied formats are:
- Once-weekly protocol: One session per week for six consecutive weeks, delivering around 3,000 pulses per session.
- Twice-weekly protocol: Two sessions per week for three weeks, then a three-week rest period with no treatment, followed by another three weeks of twice-weekly sessions. This totals twelve sessions over roughly nine weeks.
Each session typically lasts 15 to 20 minutes. The pulses are applied to multiple sites along the shaft and base of the penis. There is no recovery time needed afterward, and you can resume normal activities, including sex, the same day.
Why Spacing Between Sessions Matters
Shockwave therapy works by creating tiny mechanical forces in penile tissue that trigger a cascade of biological repair responses. The pulses stimulate the growth of new blood vessels and encourage the release of growth factors that help regenerate tissue and nerves. Research in animal models shows that stem cells in penile tissue begin proliferating within 48 hours of treatment, and nerve-supporting cells show significant growth at the same time point.
This is why sessions are spaced days apart rather than done daily. Your body needs that window to mount its repair response before the next round of stimulation. Compressing sessions too close together could blunt that healing process, while spacing them too far apart may not build enough cumulative stimulus. The once-weekly and twice-weekly formats both appear to respect this biological timeline.
When You Can Expect Results
Most men who respond to treatment notice improvements within about three months of starting. In a pilot study published in European Urology, men with blood-flow-related ED saw their erectile function scores jump from an average of 13.5 to 20.9 (on a 25-point scale) at one month after completing treatment, and those gains held steady at six months. The treated group improved by an average of 6.7 points compared to 3.0 points in a placebo group, a statistically significant difference.
Don’t expect immediate changes after your first session or two. The new blood vessel growth that drives improvement takes weeks to develop. Some men report gradual changes during the treatment course, but the full effect typically becomes apparent in the weeks following the final session.
How Long Results Last
This is the less encouraging part of the picture. Clinicians who offer shockwave therapy generally tell patients that about 50% of men who see meaningful improvement will maintain that benefit two years after treatment. That means roughly half of responders will see their gains fade over time.
Some protocols are now exploring whether maintenance sessions can extend the benefit. One clinical trial design tested six initial weekly sessions followed by a single monthly maintenance session for five months. Retreatment at six months after the original course has also been studied, with some suggestion of benefit, though those results have not reached statistical significance. If your improvements begin to fade, a repeat course is a reasonable option to discuss.
Who Responds Best
Shockwave therapy is designed primarily for vasculogenic ED, the type caused by reduced blood flow to the penis. This is the most common form of ED, particularly in men with cardiovascular risk factors like high blood pressure, high cholesterol, or smoking history. The therapy’s mechanism of growing new blood vessels makes it a logical fit for this group, and the strongest evidence supports its use in men with mild to moderate vasculogenic ED.
Results are more mixed for other causes. Men with diabetes-related ED have shown improvement in some studies but not others, particularly when ED is severe. For ED following prostate surgery, the evidence is inconsistent, with some studies showing modest improvement and others showing little benefit. The American Urological Association still classifies shockwave therapy as investigational, noting that the published trials vary widely in their methods, number of pulses, and treatment sites.
Side Effects Are Minimal
Across multiple systematic reviews, the most common finding is that patients experience no side effects at all. When side effects do occur, they are mild: slight penile pain during treatment, minor skin irritation from the ultrasound gel, or temporary local inflammation. No serious adverse events have been reported in the published literature. This safety profile is one of the therapy’s main advantages over injections, implants, or surgical options for ED.
There is no downtime between sessions. You do not need to take time off work or avoid physical activity. The treatment itself is noninvasive, performed in an office setting, and does not require anesthesia.
Putting the Schedule Together
A practical timeline for a typical course looks like this: six weekly sessions spanning six weeks, followed by a waiting period of one to three months to assess your full response. If you see meaningful improvement, no further treatment is needed until or unless the benefits diminish. If your response is partial, some providers will recommend a second course. If you are among the responders whose gains fade after a year or two, a repeat course of six sessions is the typical approach.
The total commitment for an initial course is relatively low: six office visits of about 20 minutes each, spread over six weeks, with no preparation or recovery needed. That accessibility is a large part of the therapy’s appeal, even as the evidence base continues to mature.